Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
132 studies found for:    hepatitis c phase 2 | Open Studies
Show Display Options
Rank Status Study
1 Recruiting The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
Condition: Hepatitis C Virus
Intervention:
2 Recruiting A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
Conditions: Hepatitis C Viral Infection;   Chronic Hepatitis C;   Hepatitis C (HCV);   Hepatitis C Genotype 1
Interventions: Drug: Faldaprevir;   Drug: TD-6450;   Drug: Ribavirin
3 Recruiting A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use
Condition: Hepatitis C
Intervention: Drug: Sofosbuvir (SOF)/GS-5816
4 Recruiting Efficacy and Safety of MK-3682 + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
Condition: Hepatitis C
Interventions: Drug: MK-3682;   Drug: Ruzasvir;   Drug: Ribavirin
5 Recruiting Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: Placebo
6 Recruiting Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: AL-335;   Drug: Odalasvir;   Drug: Simeprevir
7 Recruiting A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, ACH-3102, and Simeprevir
Condition: Chronic Hepatitis C
Interventions: Drug: AL-335;   Drug: ACH-3102;   Drug: Simeprevir
8 Recruiting Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
9 Recruiting Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus Associated Indolent B-cell Lymphomas
Conditions: Indolent B-cell Lymphoma;   Hepatitis C
Interventions: Drug: Sofosbuvir+Ledipasvir;   Drug: Sofosbuvir+Ribavirin;   Drug: Sofosbuvir+Ledipasvir+Ribavirin
10 Recruiting Efficacy and Safety of MK-3682 With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
Condition: Hepatitis C, Chronic
Interventions: Drug: MK-3682 450 mg;   Drug: Ruzasvir 60 mg
11 Recruiting Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF (oral tablets);   Drug: RBV;   Drug: SOF (oral granules)
12 Recruiting Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: Placebo to match LDV/SOF;   Drug: RBV
13 Recruiting Liver Test Study of Using JKB-122 in HCV-Positive Patients
Condition: Chronic Hepatitis C
Interventions: Drug: JKB-122;   Drug: Placebo
14 Recruiting 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Conditions: HIV-1 Infection;   Hepatitis C
Interventions: Drug: Ledipasvir/sofosbuvir;   Drug: Ribavirin
15 Recruiting Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
16 Recruiting Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection
Condition: Hepatitis C
Intervention: Drug: sofosbuvir
17 Recruiting Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL;   Drug: RBV
18 Recruiting Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: GS-5816
19 Not yet recruiting Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: 20mg ezetimibe;   Drug: Placebo;   Drug: 40mg ezetimibe
20 Not yet recruiting Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
Condition: Hepatitis C
Interventions: Drug: SOF/VEL for 6 weeks;   Drug: SOF/VEL for 12 weeks

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.